Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

NovaBay Pharmaceuticals (NBY) Equity Average (2016 - 2025)

NovaBay Pharmaceuticals (NBY) has disclosed Equity Average for 15 consecutive years, with $2.7 million as the latest value for Q3 2025.

  • On a quarterly basis, Equity Average rose 1076.7% to $2.7 million in Q3 2025 year-over-year; TTM through Sep 2025 was $2.7 million, a 1076.7% increase, with the full-year FY2024 number at $1.6 million, up 102.06% from a year prior.
  • Equity Average was $2.7 million for Q3 2025 at NovaBay Pharmaceuticals, down from $5.2 million in the prior quarter.
  • In the past five years, Equity Average ranged from a high of $16.7 million in Q2 2022 to a low of -$74.6 million in Q1 2023.
  • A 5-year average of -$1.2 million and a median of $5.2 million in 2025 define the central range for Equity Average.
  • Peak YoY movement for Equity Average: soared 3634.13% in 2021, then tumbled 839.02% in 2022.
  • NovaBay Pharmaceuticals' Equity Average stood at $9.8 million in 2021, then crashed by 839.02% to -$72.2 million in 2022, then skyrocketed by 107.17% to $5.2 million in 2023, then tumbled by 90.89% to $471500.0 in 2024, then surged by 467.76% to $2.7 million in 2025.
  • Per Business Quant, the three most recent readings for NBY's Equity Average are $2.7 million (Q3 2025), $5.2 million (Q2 2025), and $3.0 million (Q1 2025).